Zulresso The First FDA-Approved Drug to Treat Postpartum Depression

Zulresso: The First FDA-Approved Drug to Treat Postpartum Depression

Health

First time ever, the U.S. Food and Drug Administration (FDA) has approved a medicine aiming to treat postpartum depression. Experts say the drug will offer new hope to women and physicians to treat the condition. On Tuesday, the agency approved Sage Therapeutics Inc.’s drug for mainly designed for the state that affects a new mother’s potential to care for herself or the infant. Zulresso is the first product dispensed which will be dispensed as an IV infusion. But only a certified healthcare facility and a certified health expert could offer it. While the course may require around two-and-a-half days to complete, and starts working within a few days. It is essential to supervise the patient during the treatment because it may result in unconsciousness or sedation.

Sage funded some clinical trials to analyze the results of the drug. Thus company-funded research of new mothers involved more than 200 new mothers with moderate or severe postpartum depression. The study revealed brecanolone worked within a few hours to help to treat the condition after delivery. Many times new mothers face depression after giving birth to a baby. The situation may get more severe and long-lasting. Some common symptoms of postpartum depression include loss of interest, sadness, and negative thinking. It may lead to suicidal thoughts or difficulty to make a bond with the baby. Generally, the disorder is a type of complication in the process of childbirth and affects one in nine women. A woman can experience this type of depression during pregnancy or within four weeks of delivery.

There are many options available to treat the medical condition including counseling with a mental health expert and antidepressant medications. But none of the medicines have approval from the FDA for postpartum depression. Thus it is the first drug to gain approval from the fed agency. According to the manufacturer, the drug would cost around $20,000 – $30,000 per treatment. The first products will be available for $7,450 per vial in the U.S. So the therapy may cost about $34,000 per person before discount. The FDA said the drug would bear a black box warning indicating health risks. The treatment will be available probably in June, after completing the scheduling process by the U.S. Drug Enforcement Administration.

Leave a Reply

Your email address will not be published. Required fields are marked *